732 related articles for article (PubMed ID: 26938268)
1. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
2. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
3. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
4. Patients Present with More Advanced Prostate Cancer since the USPSTF Screening Recommendations.
Barry MJ; Nelson JB
J Urol; 2015 Dec; 194(6):1534-6. PubMed ID: 26384450
[No Abstract] [Full Text] [Related]
5. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
6. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
7. [Current results on PSA-based prostate cancer detection].
Graefen M; Schlomm T; Steuber T; Sauter G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
9. Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
Welch HG; Gorski DH; Albertsen PC
N Engl J Med; 2015 Oct; 373(18):1685-7. PubMed ID: 26510017
[No Abstract] [Full Text] [Related]
10. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
11. A population model of prostate cancer incidence.
Tsodikov A; Szabo A; Wegelin J
Stat Med; 2006 Aug; 25(16):2846-66. PubMed ID: 16397859
[TBL] [Abstract][Full Text] [Related]
12. PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.
Wachtel MS; Nelius T; Haynes AL; Dahlbeck S; de Riese W
Prostate; 2013 Sep; 73(12):1365-9. PubMed ID: 23649537
[TBL] [Abstract][Full Text] [Related]
13. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
14. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
15. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Lynch MJ
J Urol; 2005 Sep; 174(3):1155; author reply 1155-6. PubMed ID: 16094096
[No Abstract] [Full Text] [Related]
16. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
19. [PSA-screening: sensible or meaningless?].
Dubben HH
Urologe A; 2009 Sep; 48(9):1103; author reply 1103-4. PubMed ID: 19727645
[No Abstract] [Full Text] [Related]
20. Prostate Cancer Screening.
Catalona WJ
Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
